Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241 The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]
Further strengthens Poolbeg’s robust intellectual property portfolio 20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I […]
Strategic investment from the Bill & Melinda Gates Foundation with additional investment from EIFO brings the total to $11.8 million The new investment extends Series A investment to about $50 million Funds will be used to expand Freya’s DYSCOVERTM platform to identify and develop microbial immunotherapies to treat bacterial vaginosis and prevent pre-term birth COPENHAGEN, Denmark and BOSTON, Nov. 19, 2024 /PRNewswire/ — Freya […]
EMERALD Study will investigate the safety and efficacy of RTX001, an engineered macrophage cell therapy, in patients with end-stage liver disease Recruitment already underway in the U.K., following recent MHRA approval Edinburgh and London, UK, 19 November 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies in inflammatory and fibrotic […]
The Danish Centre for AI Innovation (DCAI) proudly announces that its AI supercomputer Gefion has officially ranked 21 among the world’s 500 most powerful supercomputers, according to the latest TOP500 ranking. Gefion, the recently launched AI supercomputer in Denmark, has officially been ranked as 21 on the prestigious TOP500 list of the world’s most powerful […]
